Zai Lab Limited Stock Price, News & Analysis

Zai Lab (NASDAQ: ZLAB) said members of its senior management will participate in investor conferences in November and December 2025.

Key events: a Fireside Chat on November 19, 2025 at 8:30 AM GMT at the Jefferies Global Healthcare Conference in London, and a Fireside Chat on December 2, 2025 at 1:00 PM ET at Citi's Global Healthcare Conference in Miami.

Both events will be live webcast and archived on the company's investor relations site at ir.zailaboratory.com/webcasts-presentations for up to 90 days after each event.

Zai Lab (NASDAQ: ZLAB) reported updated Phase 1 data for zocilurtatug pelitecan (zoci) in extensive-stage small cell lung cancer (ES-SCLC) as of Sept 15, 2025. In 102 evaluable patients, zoci showed high activity across doses, including a 68% ORR in the 1.6 mg/kg second-line cohort (n=19) and an 80% ORR in patients with brain metastases who had not received prior brain radiotherapy (n subset). Median duration of response was 6.1 months and median PFS was 5.4 months. Safety at 1.6 mg/kg showed 13% Grade ≥3 TRAEs and no discontinuations for toxicity in that cohort. A global Phase 3 registrational study (≈665 patients, NCT07218146) has opened for enrollment.

Zai Lab (NASDAQ: ZLAB) will report third quarter 2025 financial results and provide corporate updates on November 6, 2025, before U.S. markets open. A conference call and live webcast will follow at 8:00 a.m. ET (9:00 p.m. HKT). Participants must register in advance using the provided webcast or dial-in registration links. Dial-in details will be sent in the confirmation email after registration. A replay will be posted on the company website shortly after the call. The live webcast is accessible via the company's investor site and the listed media-server registration pages.

Zai Lab (NASDAQ: ZLAB) announced an oral presentation of updated data for zocilurtatug pelitecan (zoci) from its global Phase 1 trial (NCT06179069) at the AACR-NCI-EORTC conference in Boston, Oct 22–26, 2025.

The late-breaking abstract features additional follow-up in previously treated extensive-stage small cell lung cancer (ES-SCLC). Zai Lab said it remains on track to initiate a Phase 3 registrational study by year-end 2025. An investor webcast and conference call to discuss the data and plans is scheduled for Oct 24, 2025, 11:00 a.m. ET.

Zai Lab (NASDAQ: ZLAB) has received approval from the Hong Kong Department of Health for TIVDAK (tisotumab vedotin-tftv), a groundbreaking treatment for adult patients with recurrent or metastatic cervical cancer who experienced disease progression during or after chemotherapy.

TIVDAK represents a significant advancement as the first antibody-drug conjugate (ADC) therapy for cervical cancer, offering meaningful survival benefits. The company plans to leverage its existing ZEJULA commercial infrastructure in Hong Kong for immediate distribution. Additionally, TIVDAK's Biologics License Application is currently under review by China's National Medical Products Administration (NMPA), following its acceptance in March 2025.

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) announced its participation in two major healthcare investor conferences in September 2025. The company will present at the Cantor Global Healthcare Conference on September 4 at 10:20 a.m. ET and participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9 at 2:35 p.m. ET. Both events will take place in New York.

Investors can access live webcasts of both presentations through Zai Lab's Investor Relations website, with recordings available for 90 days after the events.

Zai Lab (NASDAQ: ZLAB) has received Innovative Medical Device Designation from China's NMPA for Tumor Treating Fields (TTFields) in pancreatic cancer treatment, following positive Phase 3 PANOVA-3 trial results. This designation enables expedited regulatory review and allows submission before approval in the country of origin.

The Phase 3 PANOVA-3 trial evaluated TTFields with gemcitabine and nab-paclitaxel as first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma. The trial met its primary endpoint with statistically significant improvement in median overall survival. Zai Lab plans to submit for regulatory approval in China in H2 2025.

Zai Lab (NASDAQ: ZLAB) has announced the formation of its Oncology Scientific Advisory Board (SAB), comprising eight distinguished leaders in oncology research and clinical practice. The advisory board will support the advancement of the company's oncology products and pipeline, including internally developed therapies.

The newly formed SAB includes prominent experts from prestigious institutions such as Yale University School of Medicine, UCLA, University of Chicago, Sarah Cannon Research Institute, University of Manchester, Yale Cancer Center, University of Pittsburgh Medical Center, and MD Anderson Cancer Center. Dr. Rafael G. Amado, President and Head of Global R&D at Zai Lab, emphasized the significance of this development for advancing innovative treatment options for patients globally.

Zai Lab (NASDAQ: ZLAB) reported Q2 2025 financial results with total revenues growing 9% year-over-year to $110.0 million. The company reaffirmed its full-year 2025 revenue guidance of $560-590 million. Operating loss improved by 28% year-over-year to $54.9 million, with the company on track to achieve profitability in Q4 2025.

Key highlights include VYVGART's record patient utilization and ZL-1310's promising clinical data showing 67% overall response rate in second-line SCLC. The successful Phase 3 FORTITUDE-101 study of bemarituzumab in gastric cancer met its primary endpoint, with China regulatory submission expected in H2 2025.

The company maintains a strong financial position with $832.3 million in cash and equivalents as of June 30, 2025, supporting its commercial expansion and pipeline development.